Header graphic for print
LimeGreenIP News

Tag Archives: patent litigation

ITC Section 337 quarterly highlights

The ITC Section 337 series provides updates on recent U.S. International Trade Commission (ITC) Section 337 investigations as well as other timely ITC developments that affect your business. The latest news round-up from our Hogan Lovells ITC Section 337 practice, includes:: Comments on the new ITC rules for practice and procedure UV Cable Coatings For Optical

Setting the right example: China’s Supreme People’s Court selects the top 10 IP cases of 2017

China’s Supreme People’s Court (“SPC”) has recently published its list of the “top 10 significant IP cases” for 2017, which it has done yearly since 2007. Although these cases are not strictly binding precedents under China’s civil law system, these cases are used as persuasive judicial guidance for China’s courts at all levels. In this

Standard essential patents in the automotive industry – Webinar recording

Earlier this month we held the third in our LimeGreen Live webinar series, in conjunction with Hogan Lovells Automotive and Mobility Industry Sector Group This webinar explored recent SEP case developments in three key jurisdictions—the U.S., Germany, and China. The speakers were three members of our global patent team handling automotive patent litigation and SEP disputes: Katie Feng (China), Joe Raffetto

Standard essential patents in the automotive industry – LimeGreen Live webinar 21/26 June

Join us on 21 or 26 June for the third in our LimeGreen Live webinar series, in conjunction with Hogan Lovells Automotive and Mobility Industry Sector Group This webinar will explore recent SEP case developments in three key jurisdictions—the U.S., Germany, and China. The presenters include three members of our global patent team handling automotive patent litigation and SEP disputes:

Video-log – Patent law in Europe: What pharmaceutical companies need to know

With pharmaceutical competition in Europe continuing to evolve, established companies and new market entrants alike need to understand how key patent litigation tools are shaping the competitive landscape. Increasing competition within Europe’s pharmaceutical space makes knowing the market and understanding available patent protections more critical than ever for both well established and new market players.

Straight Talks podcast: New players, new rules – IP disruption in the automobile industry

Not long ago, an automotive “innovation” meant a new way of engineering a powertrain or emissions system, which would then be patented by the original equipment manufacturer (OEM) or supplier. A “gentlemen’s agreement” allowed competitors to maintain similar portfolios, routinely infringe on patents, and sustain relationships that were mostly devoid of litigation. But autonomous and

US: PTAB – What’s in store for the rest of the year?

In this post we examine how Section 101, IPRs and sovereign immunity defences are set to shape the board’s procedures and strategies over the coming months. The article was first published in Intellectual Property Magazine, March 2018. Before projecting the future, it is important to reflect on the past. The US Patent Trial and Appeal Board (PTAB)

Calculating larger patent damages in China by burden shifting

In China, most damages awarded in patent cases are statutory in nature despite the availability of additional options of calculating damages including losses by the plaintiff, profits obtained by the defendant, or where a previous license exists, a royalty rate based on a multiple of the prior license agreement. Nonetheless, given there is no discovery

Hogan Lovells named MIP Global Firm of the Year

London, 9 March 2018 – Hogan Lovells global IP practice has been awarded the accolade of ‘Global IP Firm of the Year’ at the Managing Intellectual Property EMEA awards, in recognition of its market leading and innovative work on matters across Europe and beyond. The firm was shortlisted in 16 categories, also winning awards for:

Hogan Lovells partner gives Law360 a Blockchain 101 for IP attorneys

New York IP partner, Ted Mlynar was interviewed by Law360 for its recent article “What IP Attys Need to Know About Blockchain“. Ted comments on the application of blockchain technology, not solely in the financial sector, but across a wide range of industries. In this interview, Ted also discusses the blockchain patent filing trends of big businesses and the issue

Generic drugs taking hold in the Asian marketplace: STAT News interview

Aging populations and rising healthcare costs across Asia — particularly in Japan — have created new market opportunities for generic drug makers operating in the region. For originator drug manufacturers, that means increased competitive pressures, and a new urgency to protect patents. In this interview with STAT News, Tokyo partner Dr. Fred Ch’en explains the political

Wearable tech: Securing the right kind of IP protection – ‘Intellectual Values seminar series #2’ video

On 17 October 2017, Hogan Lovells, London hosted its annual ‘Intellectual Values’ seminar which this year focused on the ‘connected world’. Katie McConnell, a Counsel in our IPMT team, gave a snapshot of the issues arising from the brave new world of wearable technology. The seminar explored the IP challenges faced by market players –

U.S. Patent Legislation: The STRONGER Patents Act of 2017

In June, three democratic senators (Chris Coons from Delaware, Dick Durbin from Illinois, and Mazie Hirono from Hawaii) and one republican senator (Tom Cotton from Arkansas) introduced the “STRONGER Patents Act of 2017.” One of the motivations for the bill appears to be that the U.S. Chamber of Commerce recently ranked the U.S. patent system

US: Update on pleading standards in patent cases

It has been nearly two years since the Federal Rules of Civil Procedure were amended to eliminate Form 18, the World War II-era sample form that authorized plaintiffs to commence patent infringement litigation with only bare-bones allegations. In the absence of Form 18, it is widely accepted that patent infringement complaints are now governed by

Court of Milan rules on interim measure ordering the halt of the pricing and reimbursement procedure of a generic product

By order issued on June 18, 2017, in summary proceedings brought by Teva against Mylan and Synthon for the alleged infringement of EP 2 361 924 (covering a manufacturing process for the active ingredient glatiramer acetate), the Court of Milan revoked the interim measure granted inaudita altera parte (i.e. without the defendants have been previously

U.S. Energy disputes: Patents or trade secrets? Yes, please.

Most energy companies implement Intellectual Property (“IP”) strategies to protect and exploit company IP (offense) and navigate third-party rights (defense). Traditionally, these policies emphasize patents. But today’s IP-savvy energy companies strategically manage both patent and trade secret portfolios throughout a company’s particular energy sector focus. The ascendance of trade secrets reflects recent strengthening of U.S.

Protecting IP in the era of 3D printing

3D printing has emerged as a growing force in industries as diverse as retail, automotive, and food science. As the technology takes hold in the medical device market, it brings profound changes to product manufacturing — and to the pace of innovation. Arlene Chow says the rise in availability of 3D printed devices is already

The Patent Implications of Using AI in the Global Marketplace

International usage can lead to problems through data collection, disclosure and more. In addition to issues regarding inventorship and infringement, companies utilizing artificial intelligence (AI) and machine learning may face obstacles when training data is obtained internationally. Many applications of machine learning continually train and update the relevant models and neural networks using data collected

LSIPR Video interview – The 3D printed pill: A reality with opportunities & risks

You would be wrong to think that the 3D printed pill is “the next big thing” – it already exists and the FDA has already authorised such a pill. In an interview with Life Sciences IP Review, Stella Wong outlines why pharma and medical device companies should be looking at the opportunities and risk mitigation around this disruptive

Blockchain and patent Law: A conversation with Berkeley Law

Chris Mammen recently interviewed Berkeley Law professors Narechania and McCrary about some of the IP applications of blockchain. This short video touches upon the following points: What is blockchain? Does it have broader applications outside Finance? Who is the inventor and why is his/her/their identity important? How might ownership of a core set of blockchain patents play out in

Asia – Hot Property

Our Intellectual Property team in Asia is celebrating a run of success taking home the following 5 awards across our offices in China, Japan and Vietnam: International IP Firm of the Year (China Law & Practice Awards); Best in IP (Asialaw Asia-Pacific Dispute Resolution Award); Japan Trademark Firm of the Year (Asia IP) (Earlier this year we also